Loading...
Thumbnail Image
Publication

The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines [preprint]

Luban, Jeremy
Strambio-De-Castillia, Caterina
Wang, Yetao
Jacobson, Allan
Peltz, Stuart
Embargo Expiration Date
Link to Full Text
Abstract

The coronavirus disease 2019 (COVID-19) pandemic has created an urgent need for therapeutics that inhibit the SARS-CoV-2 virus and suppress the fulminant inflammation characteristic of advanced illness. Here, we describe the anti-COVID-19 potential of PTC299, an orally available compound that is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme of the de novo pyrimidine biosynthesis pathway. In tissue culture, PTC299 manifests robust, dose-dependent, and DHODH-dependent inhibition of SARS CoV-2 replication (EC50 range, 2.0 to 31.6 nM) with a selectivity index >3,800. PTC299 also blocked replication of other RNA viruses, including Ebola virus. Consistent with known DHODH requirements for immunomodulatory cytokine production, PTC299 inhibited the production of interleukin (IL)-6, IL-17A (also called IL-17), IL-17F, and vascular endothelial growth factor (VEGF) in tissue culture models. The combination of anti-SARS-CoV-2 activity, cytokine inhibitory activity, and previously established favorable pharmacokinetic and human safety profiles render PTC299 a promising therapeutic for COVID-19.

Source

bioRxiv 2020.08.05.238394; doi: https://doi.org/10.1101/2020.08.05.238394. Link to preprint on bioRxiv service.

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1101/2020.08.05.238394
PubMed ID
32793904
Other Identifiers
Notes

Full author list omitted for brevity. For the full list of authors, see preprint.

Funding and Acknowledgements
Corresponding Author
Related Resources

Now published in Virus Research, doi: 10.1016/j.virusres.2020.198246

Related Resources
Repository Citation
Rights
The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.